Michael Solomon

Dr. Michael Solomon has served on Protara’s board of directors since May 2018. He serves as Chief Executive Officer of Ribometrix, Inc., a company focused on targeting RNA with small molecules, and has over 20 years of experience in the biotech industry, with the last 14 years focused on creating and operating early stage companies. Most recently, Dr. Solomon served as a Venture Partner at SV Health Investors from December 2016 until December 2018 and as Chief Operating Officer at Decibel Therapeutics, Inc., a biotech company focused on hearing disorders, from 2015 until 2016, where he led the creation of Decibel’s business plan and its capital raise of $52 million. Previously, he was Chief Operating Officer at Ember Therapeutics, Inc. and Chief Business Officer at Link Medicine Corporation, a CNS company that was sold to Astra Zeneca. Dr. Solomon was a Founder and Vice President of Discovery at Epizyme Therapeutics, Inc. and Vice President of Discovery at Hypnion, Inc., a sleep disorder company that was sold to Lilly in 2007. He began his career at Millennium Pharmaceuticals, where he was a project leader for multiple programs. Dr. Solomon holds a BS in Chemistry from the University of Massachusetts, Amherst; a PhD in Organic Chemistry from the University of Wisconsin; and completed postdoctoral work in synthetic organic chemistry at Scripps.